Overview

Gender

male

Jack Pasini was elected to the Oligomerix Board of Directors in 2010 and appointed Chief Commercial Officer responsible for the development of key strategic partnerships.

Prior to joining Oligomerix, Mr. Pasini spent 30 years at Pfizer, Inc. where he held multiple senior level positions and was responsible for some of the company’s most successful brands including Spiriva, Zithromax, Diflucan and Zyvox. Among his career highlights, Mr. Pasini served as Vice President of Pfizer’s Infectious Diseases, Allergy & Respiratory Therapeutic Groups, where he led commercial decision-making involving two key therapeutic areas, generating annual revenue in excess of $5 billion. Core to the division’s success, Mr. Pasini directed Pfizer’s global Spiriva alliance with Boehringer-Ingelheim, driving annual revenue of more than $2.6 billion in 2007.

As Vice President of Product Development for Pfizer’s International Pharmaceuticals Group, Mr. Pasini led a team of 40 marketing leaders and managers in the development of strategic operating plans for multiple products, including Lipitor, Norvasc, Zithromax, Diflucan, Zoloft, Cardura and Aricept.

Mr. Pasini also served as Area President for Pfizer’s Africa-Middle East Region, Vice President of Business Intelligence and Planning and Director Commercial Development.